Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3240-3249

  Wu, Minqing ^a   Wei, Weidong ^a   Xiao, Xiangsheng ^a   Guo, Jiaoli ^a   Xie, Xinhua ^a   Li, Laisheng ^a   Kong, Yanan ^a   Lv, Ning ^a   Jia, Weihua ^a   Zhang, Yin ^a   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Breast cancer; Immunohistochemistry; Prognosis; SIRT1; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE; PROTEIN P53; SIRTUIN 1; ERBB2 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; SIRT1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; AGED; BIOSYNTHESIS; BREAST TUMOR; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIRTUIN 1; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880308453     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0260-6     Document Type: Article

References (42)

1. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417-35.
2. Imai S, Armstrong CM, Kaeberlein M, et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795-800.
3. Voelter-Mahlknecht S, Mahlknecht U. Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1. Int J Mol Med. 2006;17(1):59-67.
4. Vaziri H, Dessain SK, Ng EE, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107(2):149-59.
5. Luo J, Su F, Chen D, et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408(6810):377-81.
6. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell. 2004;116(4):551-63.
7. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell. 2004;13(5):627-38.
8. Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes. 2009;58(2):344-51.
9. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002;21(10):2383-96.
10. Jung-Hynes B, Nihal M, Zhong W, et al. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem. 2009;284(6):3823-32.
11. Cha EJ, Noh SJ, Kwon KS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 2009;15(13):4453-9.
12. Jang KY, Kim KS, Hwang SH, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 2009;41(4):366-71.
13. Choi HN, Bae JS, Jamiyandorj U, et al. Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep. 2011;26(2):503-10.
14. Jang KY, Hwang SH, Kwon KS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 2008;32(10):1523-31.
15. DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409-18.
16. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-502.
17. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-34.
18. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
19. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-74.
20. Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42(18):3149-56.
21. Sung JY, Kim R, Kim JE, et al. Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci. 2010;101(7):1738-44.
22. Lee H, Kim KR, Noh SJ, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol. 2011;42(2):204-13.
23. Tavassaoeli FA, Davilee P. Tumors of the breast and female genital organs. Classification of tumours. No 4. Lyon: IARC WHO; 2003.
24. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.
25. Friedrichs K, Gluba S, Eidtmann H, et al. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993;72(12):3641-7.
26. Galgano MT, Hampton GM, Frierson HJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19(6):847-53.
27. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE. 2008;3(4):e2020.
28. Dai Y, Ngo D, Forman LW, et al. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol. 2007;21(8):1807-21.
29. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23(12):2369-80.
30. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-10.
31. Lozano G, Elledge SJ. p53 sends nucleotides to repair DNA. Nature. 2000;404(6773):24-5.
32. Schimmelpenning H, Eriksson ET, Zetterberg A, et al. Association of immunohistochemical p53 tumor suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas. World J Surg. 1994;18(6):827-32, 832-33.
33. Bhargava V, Thor A, Deng G, et al. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol. 1994;7(3):361-8.
34. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107(2):137-48.
35. Lim CS. Human SIRT1: a potential biomarker for tumorigenesis? Cell Biol Int. 2007;31(6):636-7.
36. Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 2005;123(3):437-48.
37. Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA. 2003;100(19):10794-9.
38. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9(Suppl 2):S73-81.
39. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J. 2009;15(5):454-60.
40. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008;14(5):456-63.
41. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006;37(9):1217-26.
42. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568-81.